import
effort
perform
emerg
sever
acut
respiratori
syndrom
sar
epidem
diagnos
prevent
viru
spread
sever
type
vaccin
develop
includ
inactiv
virus
subunit
vaccin
viruslik
particl
vlp
dna
vaccin
heterolog
express
system
vaccin
deriv
sarscov
genom
revers
genet
review
describ
sever
aspect
essenti
develop
sarscov
vaccin
correl
protect
viru
serotyp
vaccin
side
effect
biosafeguard
engin
recombin
vaccin
approach
base
sarscov
genom
product
effect
safe
vaccin
prevent
sar
led
develop
promis
vaccin
candid
contrast
design
vaccin
coronavirus
gener
less
success
preclin
trial
anim
model
efficaci
safeti
evalu
promis
vaccin
candid
describ
perform
human
sever
acut
respiratori
syndrom
sar
infecti
diseas
caus
coronaviru
sarscov
marra
et
al
rota
et
al
sar
detect
first
time
guandong
provinc
china
late
spread
rapidli
around
world
result
case
result
death
countri
area
five
contin
http
wwwcdcgovmmwrmguid
sarsenhtml
world
healh
organ
declar
end
sar
outbreak
juli
nevertheless
sever
isol
outbreak
subsequ
occur
accident
contamin
laboratori
taiwan
singapor
mainland
china
http
wwwwhointcsrsarsen
late
earli
newli
infect
person
contact
anim
infect
sarscov
strain
significantli
differ
predomin
outbreak
report
outbreak
sera
sampl
collect
posit
case
zheng
et
al
furthermor
anim
trader
wherea
veget
trader
guandong
market
seroposit
sarscov
without
show
sign
diseas
guan
et
al
sarscov
vaccin
urgent
need
prevent
potenti
sar
epidem
sarscov
diseas
sever
link
age
higher
mortal
age
special
attent
paid
vaccin
develop
protect
elderli
peopl
sever
type
vaccin
develop
includ
inactiv
virus
subunit
vaccin
viruslik
particl
vlp
dna
vaccin
heterolog
express
system
vaccin
deriv
sarscov
genom
revers
genet
paper
review
previous
publish
sar
vaccin
strategi
announc
new
accomplish
sarscov
base
vaccin
approach
focus
correl
protect
detect
serotyp
vaccin
side
effect
biosafeguard
engin
recombin
vaccin
approach
base
sarscov
genom
knowledg
divers
serotyp
essenti
inform
vaccin
design
phylogenet
analysi
sarscov
isol
anim
human
strongli
suggest
viru
origin
anim
like
bat
poon
et
al
amplifi
palm
civet
transmit
human
popul
via
live
anim
market
kan
et
al
neutral
set
eight
pseudovirus
express
spike
glycoprotein
eight
sarscov
strain
select
three
phase
sar
epidem
earli
middl
late
plu
anoth
human
isol
collect
end
two
civet
cat
isol
studi
chineseconsortium
yang
et
al
human
monoclon
antibodi
protein
frankfurt
isol
deriv
epsteinbarr
viru
transform
b
lymphocyt
use
viru
test
neutral
assay
includ
pseudotyp
made
protein
member
four
main
genet
cluster
defin
bayesian
analysi
sarscov
glycoprotein
fig
group
origin
anim
isol
prototyp
group
isol
primarili
use
civet
human
angiotensinconvert
enzym
receptor
ii
group
low
pathogen
virus
origin
civet
raccoon
dog
sporad
human
case
strain
report
sporad
sar
case
decemb
viru
repres
independ
introduct
less
pathogen
viru
glycoprotein
sequenc
diverg
human
strain
chineseconsortium
gener
group
isol
appear
receptor
bind
domain
rbd
capabl
recogn
human
receptor
success
cultur
glycoprotein
contain
amino
acid
substitut
rel
group
urbani
multipl
sequenc
align
spike
gene
viru
creat
use
clustalx
default
set
bayesian
infer
conduct
mr
bay
markov
chain
mont
carlo
sampl
four
chain
gener
consensu
tree
gener
use
major
rule
burn
branch
confid
valu
shown
posterior
probabl
three
human
isol
fall
within
anim
cluster
may
repres
infect
human
acquir
viru
anim
dash
line
group
group
use
repres
much
longer
line
tree
time
longer
thu
distanc
line
repres
distanc
bat
human
sar
protein
mani
map
within
neutral
epitop
amino
acid
correspond
rbd
recombin
virus
encod
glycoprotein
isol
use
revers
genet
recombin
viru
replic
log
less
effici
human
airway
epitheli
cell
pfuml
compar
wt
urbani
pfuml
h
postinfect
iii
group
highli
pathogen
virus
repres
epidem
strain
associ
earli
middl
late
phase
prototyp
virus
earli
isol
middl
isol
cuhkw
respect
late
urbani
toronto
strain
iv
group
bat
sarscov
strain
success
cultur
sequenc
sampl
taken
rhinolophu
spp
like
chines
horsesho
bat
virus
differ
urbani
amino
acid
sequenc
gener
contact
interfac
residu
human
receptor
use
glycoprotein
gene
unroot
bayesian
analysi
suggest
bat
strain
close
relat
earli
phase
human
strain
basic
viru
pseudotyp
protein
differ
strain
neutral
extent
except
human
two
civet
cat
isol
indic
least
two
human
sarscov
serotyp
like
origin
two
independ
transmiss
viru
civet
cat
human
yang
et
al
import
determin
recombin
virus
bear
zoonot
glycoprotein
display
similar
neutral
kinet
pseudotyp
virus
bear
sar
spike
sarscovlik
isol
bat
identifi
rhinolophu
spp
nucleotid
ident
strain
higher
li
et
al
addit
six
novel
coronavirus
six
differ
bat
speci
describ
woo
et
al
four
coronavirus
belong
group
two
group
base
sequenc
data
author
propos
classif
bat
cov
three
subgroup
subgroup
compris
sarscov
batsarscov
isol
sequenc
sarscov
isol
differ
domain
protein
sequenc
ident
fell
sequenc
diverg
domain
corrobor
serum
neutral
studi
indic
although
bat
sera
high
level
crossreact
antibodi
fail
neutral
human
civet
cat
sarscov
test
vero
cell
contrast
author
report
bat
sera
sampl
test
neutral
human
sarscov
isol
use
cell
discrep
could
due
presenc
differ
sarscovlik
viru
serotyp
bat
studi
two
differ
group
two
test
system
use
evalu
consequ
vaccin
design
take
account
antigen
divers
interestingli
recent
character
antigen
structur
sarscov
protein
larg
panel
mab
shown
least
one
epitop
provid
suscept
sarscov
map
rbd
highli
conserv
viru
strain
therefor
may
confer
protect
sarscov
strain
et
al
sarscov
least
seven
structur
protein
e
n
fig
schaecher
pekosz
weiss
navasmartin
sarscov
e
protein
viral
membran
protein
domain
expos
extern
face
viru
ito
et
al
shen
et
al
principl
could
involv
protect
induct
neutral
antibodi
shown
protein
induc
vitro
sarscov
neutral
antibodi
protein
main
compon
protect
immun
qiu
et
al
saif
although
strong
immun
respons
elicit
n
protein
subbarao
et
al
wang
et
al
zhu
et
al
passiv
transfer
studi
illustr
sspecif
antibodi
confer
protect
sarscov
replic
mous
model
bisht
et
al
subbarao
et
al
relev
protein
protect
sarscov
reinforc
identif
neutral
antibodi
convalesc
patient
major
coronaviru
neutral
epitop
locat
within
spike
protein
viru
hogan
et
al
two
domain
defin
spike
protein
aminoterminu
carboxyterminu
halv
coronavirus
appar
case
sarscov
protein
process
two
halv
weiss
navasmartin
wong
et
al
recent
evid
determin
sarscov
neutral
sensit
deglycosyl
spike
protein
suggest
conform
epitop
import
antibodi
recognit
song
et
al
rbd
locat
subunit
protein
contain
multipl
conform
neutral
epitop
suggest
recombin
protein
contain
rbd
vector
encod
rbd
sequenc
use
develop
safe
effect
sar
vaccin
continu
viral
epitop
target
antibodi
plasma
sampl
convalesc
sar
patient
identifi
biopan
phage
display
dodecapeptid
librari
epitop
converg
short
peptid
fragment
one
spike
nucleocapsid
protein
immunoassay
found
patient
recov
sar
develop
antibodi
epitoperich
region
spike
domain
indic
domain
also
immunodomin
site
protein
antibodi
shown
effect
neutral
sarscov
moreov
possibl
antibodi
provid
protect
immun
help
patient
recov
viral
infect
fact
among
rabbit
antibodi
elicit
differ
fragment
cover
entir
protein
express
e
coli
specif
aa
includ
heptadrepeat
sequenc
domain
interact
form
protein
trimer
neutral
activ
indic
region
protein
also
carri
neutral
epitop
sarscov
protein
consist
amino
acid
contain
three
put
transmembran
domain
express
viru
cell
surfac
ito
et
al
tan
et
al
topolog
protein
cell
surfac
experiment
determin
first
aa
locat
first
transmembran
domain
face
extracellular
matrix
akerstrom
et
al
ctermin
third
transmembran
domain
aa
face
cytoplasm
tan
et
al
interestingli
two
separ
cohort
sar
patient
one
taiwan
hong
kong
b
cell
recogn
ntermin
region
protein
isol
patient
moreov
signific
proport
convalesc
sar
patient
examin
dot
blot
assay
use
synthet
peptid
sequenc
correspond
amino
acid
n
terminu
protein
posit
addit
recent
report
ntermin
domain
protein
elicit
strong
potenti
protect
humor
respons
infect
patient
zhong
et
al
accordingli
rabbit
polyclon
antibodi
rais
synthet
peptid
correspond
aa
protein
inhibit
sarscov
propag
vero
cell
contrast
antibodi
specif
ctermin
domain
protein
akerstrom
et
al
sarscov
e
protein
shown
low
immunogen
tan
et
al
sera
three
convalesc
phase
sar
patient
recogn
protein
express
mammalian
cell
accordingli
sarscov
e
protein
peptid
recogn
convalesc
patient
antisera
use
protein
microarray
qiu
et
al
studi
use
rabbit
antibodi
recombin
fragment
associ
sarscov
e
n
protein
strong
neutral
antibodi
elicit
fragment
aa
protein
qiu
et
al
incorrect
fold
protein
express
e
coli
could
respons
lack
detect
antibodi
viral
protein
protein
known
induc
neutral
antibodi
see
protein
transmiss
gastroenter
coronaviru
tgev
requir
viru
assembl
bud
protein
specif
antibodi
significantli
weakli
neutral
tgev
mediat
complementdepend
lysi
tgev
infect
cell
delma
et
al
risco
et
al
wood
et
al
consist
tgev
data
describ
shown
sarscov
protein
also
induc
viru
neutral
antibodi
absenc
complement
addit
mixtur
protein
show
synergist
effect
vitro
synthesi
tgev
neutral
antibodi
immun
leukocyt
case
sarscov
immun
hamster
parainfluenza
viru
vector
shown
differenti
role
e
n
protein
protect
parainfluenza
viru
express
protein
alon
provid
complet
protect
sarscov
challeng
lower
respiratori
tract
partial
protect
upper
respiratori
tract
protect
slightli
augment
coexpress
e
protein
nevertheless
express
e
n
protein
absenc
protein
confer
detect
protect
result
identifi
main
sarscov
neutral
protect
antigen
among
structur
protein
confer
limit
role
sarscov
protein
protect
sarscov
n
protein
specif
antibodi
neutral
viru
vitro
could
expect
intern
viru
protein
pang
et
al
howev
sarscov
n
protein
induc
tcell
respons
gao
et
al
accordingli
dna
immun
use
sarscov
n
gene
induc
potent
polar
immun
respons
mice
well
specif
antibodi
anim
fact
highest
level
humor
respons
cell
prolifer
activ
induc
n
gene
construct
jin
et
al
analysi
immun
respons
anoth
coronaviru
tgev
use
vitro
antibodi
synthesi
system
shown
optimum
combin
viral
protein
stimul
product
tgev
neutral
antibodi
vitro
mixtur
n
protein
combin
protein
oligom
rosett
n
n
proteinderiv
peptid
anton
et
al
anton
et
al
data
principl
suggest
n
protein
could
use
vaccin
promot
synthesi
sspecif
neutral
antibodi
protein
aa
elicit
antibodi
sarscov
patient
indic
express
natur
diseas
immunogen
qiu
et
al
zhong
et
al
fact
convalesc
phase
patient
sera
posit
protein
base
data
specul
protein
could
structur
qiu
et
al
nevertheless
presenc
protein
sarscov
virion
need
prove
summari
avail
data
sarscov
protein
elicit
strong
neutral
antibodi
respons
wherea
protein
induc
reduc
neutral
humor
immun
respons
antigen
probabl
relev
protect
sarscov
addit
structur
protein
e
n
possibl
protein
could
also
play
role
protect
studi
role
humor
immun
respons
sarscov
spike
specif
monoclon
antibodi
neutral
viru
develop
subbarao
et
al
traggiai
et
al
zhang
et
al
passiv
transfer
monoclon
antibodi
immun
serum
mice
protect
infect
sarscov
use
epsteinbarr
viru
transform
human
b
cell
memori
repertoir
patient
recov
sarscov
infect
rescu
traggiai
et
al
monoclon
antibodi
exhibit
neutral
activ
vitro
also
confer
protect
mous
model
sarscov
infect
addit
human
igg
monoclon
antibodi
neutral
sarscov
develop
use
phage
display
librari
protect
ferret
lung
diseas
viru
shed
pharyng
secret
ter
meulen
et
al
mous
ferret
model
administr
human
monoclon
antibodi
vitro
neutral
activ
reduc
sarscov
titer
lung
protect
lung
patholog
ferret
ter
meulen
et
al
overal
data
indic
humor
immun
respons
alon
protect
sar
immun
respons
sarscov
elicit
dna
vaccin
encod
codon
optim
sar
spike
protein
fragment
induc
neutral
antibodi
zeng
et
al
well
tcell
respons
nevertheless
protect
sarscov
challeng
mediat
humor
immun
respons
tcelldepend
mechan
surprisingli
immunodefici
mice
clear
sarscov
infect
show
role
innat
immun
respons
defens
sarscov
mice
lack
nkt
cell
nk
cell
lack
b
cell
ragl
clear
viru
day
infect
glass
et
al
display
high
induct
proinflammatori
cytokin
data
suggest
nk
cell
adapt
immun
respons
essenti
viru
clearanc
mice
possibl
interferon
pathway
relev
viral
clearanc
import
interferon
respons
reinforc
infect
mice
sarscov
hogan
et
al
import
regul
interferon
mice
produc
one
hundredfold
increas
viral
titer
control
mice
addit
mutant
mice
develop
interstiti
pneumonia
seen
control
mice
hogan
et
al
alveolar
damag
seen
lung
human
patient
unclear
time
observ
patholog
differ
human
stat
mous
lung
due
time
sampl
differ
host
respons
hogan
et
al
neutral
antibodi
detect
week
onset
diseas
immunocompet
sar
patient
patient
recov
without
hospit
data
indic
patient
success
respond
sarscov
infect
although
mani
type
vaccin
sarscov
attempt
express
recombin
protein
use
viru
vector
vaccin
requir
consider
research
setup
time
bradburi
therefor
classic
approach
use
inactiv
cellcultur
base
sarscov
like
easiest
way
sar
vaccin
develop
base
experi
avail
vaccin
includ
inactiv
live
polio
rabi
vaccin
montagnon
zhou
et
al
case
compani
favor
develop
inactiv
candid
whole
viru
vaccin
base
wellestablish
technolog
develop
vaccin
spruth
et
al
fast
spread
sar
initi
prompt
chines
compani
sinovac
biotech
beijin
develop
vaccin
collabor
chines
academi
medic
scienc
start
test
vaccin
inactiv
form
sarscov
earli
use
volunt
marshal
enserink
side
effect
report
first
patient
inject
inactiv
viru
sarscov
inactiv
produc
kill
vaccin
perform
use
differ
method
instanc
sarscov
purifi
ultracentrifug
inactiv
administ
without
alhydrogel
adjuv
see
et
al
viru
subcutan
administ
mice
effici
recombin
adenovirus
express
either
n
protein
provid
intranas
intramuscular
rout
altern
method
inactiv
sarscov
initi
purif
step
immun
viru
compar
vaccin
use
dna
adenoviru
vector
humor
immun
respons
effect
use
inactiv
viru
adjuv
chiron
vaccin
alum
pierc
rockkford
il
associ
stimul
respons
support
use
inactiv
sarscov
vaccin
sarscov
also
purifi
homogen
ultrafiltr
gel
filtrat
exchang
chromatographi
inactiv
cynomolgu
macaqu
immun
differ
amount
purifi
viru
absenc
presenc
adjuv
monkey
challeng
nasal
rout
day
postimmun
high
level
neutral
antibodi
prevent
replic
sarscov
interstiti
pneumonia
induc
qin
et
al
interestingli
side
effect
observ
even
presenc
low
titer
neutral
antibodi
indic
purifi
sarscov
vaccin
safe
monkey
approach
sarscov
partial
purifi
sucros
cushion
complet
inactiv
formaldehyd
viru
effici
compet
bind
infecti
viru
cell
indic
inactiv
viru
kept
function
rb
qu
et
al
polyethyleneglycol
precipit
viru
alon
presenc
cholera
toxin
b
ctb
sigma
cpg
administ
mice
intranas
rout
elicit
serum
sarscovspecif
neutral
antibodi
iga
specif
antibodi
trachea
lung
qu
et
al
anoth
approach
formaldehyd
inactiv
whole
viru
prepar
vero
cell
use
intramuscular
immun
yearold
rhesu
monkey
week
monkey
challeng
sarscov
dose
gmonkey
protect
monkey
challeng
pfu
sarscov
higher
dose
g
confer
complet
protect
contrast
control
anim
develop
typic
sarscov
infect
challeng
immun
preferenti
induc
respons
also
enhanc
cellular
immun
respons
includ
product
increas
activ
natur
killer
cell
inhibit
viru
replic
system
side
effect
observ
vaccin
anim
postimmun
even
high
dose
gmonkey
two
inject
one
vaccin
manufactur
larg
scale
use
ferment
cultur
vero
cell
serum
free
medium
base
doubleinactiv
whole
viru
vaccin
spruth
et
al
viru
infect
moi
result
gener
high
viral
titer
around
tcid
ml
cultur
supernat
harvest
inactiv
formalin
treatment
follow
uv
inactiv
two
step
inactiv
procedur
util
order
ensur
high
safeti
margin
respect
residu
infect
mice
immun
twice
l
g
sarscov
vaccin
use
adjuv
aluminium
hydroxid
develop
high
antibodi
titer
sarscov
spike
protein
determin
elisa
test
use
adjuv
al
oh
minor
effect
immunogen
vaccin
addit
cell
mediat
immun
measur
product
stimul
elicit
vaccin
confer
protect
correl
antibodi
titer
sarscov
protein
neutral
antibodi
titer
induct
neutral
antibodi
titer
sspecif
elisa
titer
result
protect
intranas
challeng
tcid
infecti
viru
polypeptid
contain
amino
acid
sarscov
spike
protein
express
use
baculoviru
system
bisht
et
al
affin
purifi
protein
administ
mice
either
saponin
ribi
adjuv
regimen
induc
bind
neutral
monoclon
antibodi
although
best
result
obtain
saponin
polypeptid
provid
highest
antibodi
respons
challeng
protect
immun
shown
reduct
sarscov
titer
upper
lower
respiratori
tract
subunit
vaccin
induc
higher
neutral
antibodi
complet
protect
intranas
challeng
achiev
inocul
mice
live
sarscov
vaccinia
viru
ankara
mva
express
full
length
protein
bisht
et
al
dna
express
fulllength
protein
lack
transmembran
cytoplasm
domain
n
protein
provid
protect
sarscov
infect
still
larg
number
report
use
n
protein
antigen
publish
immun
respons
mice
vaccin
purifi
n
protein
fuse
glutathion
stransferas
gst
analyz
compar
respons
two
dnabas
vaccin
approach
gupta
et
al
immun
ngst
elicit
strong
tcell
antibodi
respons
minim
respons
respons
differ
markedli
immun
respons
shown
mice
immun
dna
encod
unmodifi
cytoplasm
n
protein
dna
encod
n
chimera
target
lysosom
mhc
ii
compart
dna
immun
elicit
strong
tcell
ctl
respons
nevertheless
tcell
respons
three
immunogen
elicit
n
peptid
shown
elispot
analysi
antigenactiv
cell
vivo
protect
experi
perform
vaccin
n
protein
sarscov
express
e
coli
purifi
balbc
mice
vaccin
n
protein
emulsifi
montanid
contain
oligodeoxynucleotid
cpg
pb
first
case
antin
antibodi
found
mainli
suggest
preval
immun
respons
contrast
antin
protein
antibodi
mice
immun
n
protein
pb
found
mainli
reactiv
antisera
rais
n
protein
formul
mice
monkey
sera
patient
test
panel
overlap
peptid
region
around
residu
n
protein
immunogen
three
model
addit
peptid
correspond
residu
contain
murin
immunodomin
tcell
epitop
use
secret
cell
assay
peptid
contain
residu
capabl
stimul
cell
prolifer
vitro
peptid
correspond
residu
capabl
stimul
product
tcell
cultur
deriv
peripher
blood
mononuclear
cell
pbmc
macaqu
immun
n
protein
emulsifi
protect
experi
perform
immunogen
requir
sarscov
vlp
format
differ
use
differ
express
system
cell
type
product
viral
protein
insect
cell
use
baculoviru
shown
intracellular
sarscov
vlp
assembl
express
e
protein
ho
et
al
secret
vlp
extracellular
media
requir
coexpress
protein
mortola
roy
experi
secret
vlp
rel
effici
g
per
infect
cell
result
varianc
obtain
express
sarscov
protein
human
renal
epitheli
cell
control
cytomegaloviru
promot
use
dna
plasmid
system
combin
gene
express
n
protein
without
e
protein
gener
intracellular
vlp
pseudoparticl
form
absenc
n
protein
singl
viral
gene
abl
support
format
viral
capsid
within
cell
addit
express
protein
allow
format
bud
particl
morpholog
typic
sar
relat
coronavirus
differ
type
vlp
could
form
depend
protein
composit
sarscov
vlp
protect
administr
vlp
report
develop
plantbas
vaccin
differ
coronavirus
tgev
infecti
bronchiti
viru
ibv
porcin
epidem
diarrhea
viru
pedv
use
oral
deliveri
recombin
protein
elicit
protect
immun
report
bae
et
al
lamphear
et
al
tuboli
et
al
zhou
et
al
one
studi
includ
protein
plantbas
vaccin
candid
tgev
advanc
earli
phase
farm
trial
tuboli
et
al
recent
develop
safe
effect
inexpens
vaccin
candid
domain
sarscov
protein
express
tomato
lownicotin
tobacco
plant
pogrebnyak
et
al
high
express
level
recombin
protein
total
solubl
protein
observ
sever
transgen
line
western
blot
analysi
use
protein
specif
antibodi
plantderiv
antigen
induc
system
mucos
immun
respons
mice
show
significantli
increas
level
sarscov
specif
iga
oral
ingest
tomato
fruit
express
protein
pogrebnyak
et
al
sera
mice
parenter
prime
tobaccoderiv
protein
reveal
presenc
sarscovspecif
igg
sever
approach
base
dna
vaccin
describ
order
elicit
protect
sar
two
use
primeboost
strategi
show
combin
dna
vaccin
whole
chemic
inactiv
vaccin
use
enhanc
magnitud
immun
respons
also
chang
balanc
humor
cellular
immun
respons
zakhartchouk
et
al
combin
dna
inactiv
viru
induc
immun
respons
whole
kill
viru
vaccin
induc
immun
respons
mice
immun
intramuscularli
dna
vaccin
express
protein
intraperiton
boost
e
coli
express
peptid
show
high
neutral
titer
vaccin
might
practic
valu
immun
farm
grow
civet
cat
due
low
cost
dna
vaccin
express
n
protein
alon
link
calreticulin
first
one
preferenti
induc
igg
respons
isotyp
ctl
respons
n
protein
produc
strong
delayedtyp
hypersensit
dth
could
undesir
side
effect
express
n
protein
link
calreticulin
increas
major
histocompat
complex
mhc
class
present
cell
absenc
report
advers
effect
mice
kim
et
al
vaccin
led
gener
strong
nspecif
humor
tcellmedi
immun
respons
mice
protect
experi
shown
n
protein
also
express
link
hlamp
nhlamp
target
antigen
mhc
class
ii
lead
stronger
higher
memori
cellular
immun
respons
associ
high
product
immun
n
protein
alon
gupta
et
al
studi
dna
immun
protect
sar
use
three
form
spike
protein
fulllength
protein
cytoplasm
transmembran
domain
delet
report
vaccin
induc
neutral
antibodi
tcell
respons
result
protect
immun
mice
viral
replic
reduc
six
order
magnitud
lung
mice
vaccin
plasmid
dna
express
vector
protect
mediat
humor
tcell
depend
immun
mechan
shown
adopt
tcell
transfer
donor
tcell
unabl
reduc
pulmonari
viral
replic
recipi
anim
contrast
passiv
transfer
purifi
igg
immun
mice
control
igg
provid
immun
protect
sarscov
vector
express
protein
cytoplasm
domain
partial
delet
induc
potent
neutral
antibodi
respons
use
highli
attenu
modifi
mva
sarscov
protein
express
sever
group
bisht
et
al
chen
et
al
first
one
shown
intranas
intramuscular
immun
balbc
mice
elicit
protect
immun
shown
reduct
sarscov
titer
upper
lower
respiratori
tract
challeng
furthermor
passiv
transfer
serum
mice
immun
recombin
mva
express
protein
mice
also
reduc
replic
sarscov
respiratori
tract
challeng
demonstr
role
protein
specif
antibodi
protect
second
group
show
induct
neutral
antibodi
mice
ferret
monkey
although
protect
experi
perform
antibodi
absorpt
assay
major
antibodi
rais
mva
recombin
express
fulllength
protein
absorb
protein
fragment
includ
aa
includ
rbd
indic
major
sarscov
neutral
mechan
like
occur
block
interact
viru
cellular
receptor
contrast
author
immun
ferret
use
mva
express
sarscov
protein
induc
vigor
immun
respons
prevent
viru
infect
spread
czub
et
al
weingartl
et
al
liver
inflamm
found
mvaspik
vaccin
ferret
author
suggest
result
indic
induct
antibodi
depend
enhanc
ade
diseas
similar
caus
felin
infecti
periton
viru
fipv
sar
vaccin
base
use
adenoviru
vector
shown
express
protein
alon
combin
n
protein
led
protect
mice
challeng
sarscov
efficaci
immun
adenoviru
vector
compar
chemic
inactiv
partial
purifi
viru
wholekil
viru
vaccin
effect
confer
protect
immun
live
sarscov
see
et
al
adenoviru
vaccin
test
mice
express
either
n
protein
zakhartchouk
et
al
shown
domain
n
protein
contain
strong
tcell
epitop
report
challeng
experi
monkey
model
adenovirusbas
vaccin
induc
strong
sarscovspecif
immun
respons
indic
vector
promis
vaccin
candid
inform
protect
provid
gao
et
al
adenoviru
vector
delet
region
also
use
express
domain
sarscov
protein
aa
wistar
rat
immun
three
time
throughout
consecut
week
produc
antiserum
capabl
protect
sarscov
infect
cell
cultur
histopatholog
examin
found
evid
side
effect
immun
anim
nevertheless
vivo
protect
experi
perform
therefor
addit
experi
requir
adenoviru
base
sar
vaccin
sever
diseas
high
death
rate
note
senesc
human
popul
infect
sarscov
children
year
age
develop
sever
diseas
seen
adult
deme
et
al
data
suggest
qualiti
immun
respons
may
play
role
outcom
viru
infect
abil
vaccin
induc
robust
immun
respons
senesc
popul
evalu
determin
protect
elicit
elderli
popul
senesc
immun
system
evalu
vaccin
efficaci
homolog
heterolog
strain
urbani
glycoprotein
nucleocapsid
gene
insert
vee
viru
replicon
particl
vrp
vrpn
deme
et
al
addit
express
influenza
ha
glycoprotein
vrpha
use
control
use
revers
genet
synthet
resurrect
recombin
virus
bear
glycoprotein
replic
high
titer
vero
human
airway
epitheli
cell
obtain
deme
et
al
importantli
human
convalesc
sera
plaqu
reduct
neutral
titr
prnt
valu
late
phase
isol
like
urbani
yet
reduc
fold
heterolog
viru
prnt
fig
young
senesc
balbc
mice
age
exceed
year
time
challeng
vaccin
vrpha
vrp
vrpn
combin
vrp
vrpn
challeng
recombin
sarscov
express
urbani
protein
antigen
differ
protein
fig
vaccin
anim
vrp
vaccin
provid
complet
shortand
longterm
protect
homolog
challeng
protect
young
senesc
mice
urbani
strain
replic
challeng
vrp
vrp
vrpn
vaccin
mice
display
littl
patholog
lesion
lung
wherea
vrpha
vaccin
age
mice
demonstr
patholog
lesion
lung
similar
report
literatur
robert
et
al
vrp
vaccin
also
provid
shortterm
protect
young
mice
challeng
heterolog
strain
despit
significantli
reduc
abil
antiurbani
antibodi
neutral
viru
express
contrast
vaccin
senesc
mice
vrp
provid
limit
protect
combin
vrp
vrpn
vaccin
provid
littl
longterm
protect
infect
antigen
differ
sarscov
although
viru
titer
reduc
compar
vrpha
control
sarscov
challeng
also
produc
patholog
lesion
vrpha
sarsvaccin
anim
virtual
indistinguish
produc
infect
sarscovurbani
strain
therefor
like
declin
immun
senesc
anim
combin
reduc
abil
antibodi
neutral
heterolog
challeng
virus
result
vaccin
failur
age
anim
seem
vaccin
approach
induc
less
robust
neutral
respons
like
dna
kill
vaccin
might
complet
fail
protect
senesc
popul
sarscov
challeng
sarscov
diseas
sever
link
age
comorbid
mortal
rate
increas
age
exceed
individu
also
known
elderli
respond
poorli
new
antigen
compar
younger
popul
overal
phenomena
poorli
studi
consequ
vaccin
efficaci
elderli
key
properti
efficaci
sarscov
vaccin
immunosenesc
common
anim
model
clinic
studi
occur
age
vaccin
efficaci
often
attenu
elderli
frasca
et
al
song
et
al
zheng
et
al
immun
complic
includ
gener
decreas
function
b
cell
innat
immun
function
diminish
macrophag
granulocyt
function
diminish
cellular
traffic
cell
growth
differenti
decreas
natur
killer
cell
number
activ
new
differ
vaccin
regimen
develop
test
ultim
goal
elicit
complet
protect
antigen
heterolog
form
sarscov
especi
vulner
elderli
popul
need
test
develop
vaccin
induc
antin
respons
anim
model
similarli
describ
viral
system
frech
et
al
mcelhaney
vector
base
exist
live
attenu
parainfluenza
viru
develop
intranas
pediatr
immu
nizat
human
parainfluenza
viru
type
use
express
sarscov
protein
vector
administr
monkey
result
product
system
immun
respons
mucos
immun
challeng
sarscov
monkey
control
group
shed
sarscov
contrast
viral
shed
occur
group
immun
parainfluenza
vector
express
protein
recombin
virus
express
sarscov
structur
n
protein
individu
combin
evalu
immunogen
protect
hamster
support
replic
sarscov
parainfluenza
vector
singl
intranas
administr
vector
express
glycoprotein
induc
high
titer
sarscov
neutral
antibodi
two
fold
lower
induc
sarscov
infect
respons
provid
complet
protect
sarscov
challeng
lower
respiratori
tract
partial
protect
upper
respiratori
tract
contrast
express
n
e
protein
induc
detect
serum
sarscov
neutral
antibodi
recombin
rabi
viru
vector
use
express
protein
sarscov
faber
et
al
immunogen
studi
mice
show
induct
sarscov
neutral
antibodi
singl
dose
protect
studi
shown
similarli
attenu
vesicular
stomat
viru
vsv
vector
use
express
protein
sarscov
kapadia
et
al
mice
vaccin
vsv
develop
sarscov
neutral
antibodi
control
challeng
sarscov
perform
month
singl
vaccin
summari
immun
prevent
sar
use
differ
live
vector
system
shown
protect
mainli
mediat
humor
immun
respons
protein
warn
signal
least
vector
vee
viru
express
n
protein
may
lead
side
effect
effect
delet
groupspecif
gene
differ
coronavirus
studi
report
use
mous
hepat
viru
mhv
model
shown
delet
mutant
remov
orf
attenu
natur
host
de
haan
et
al
similarli
studi
delet
orf
tgev
ortego
et
al
orf
fipv
haijema
et
al
led
viru
attenu
howev
sarscov
delet
mutant
lack
orf
significantli
influenc
vitro
vivo
replic
effici
mous
model
yount
et
al
recombin
virus
replic
wildtyp
level
murin
model
suggest
either
groupspecif
orf
play
littl
role
vivo
replic
effici
mous
model
suffici
qualiti
discern
role
groupspecif
orf
diseas
fact
surpris
orf
like
encod
structur
viru
protein
schaecher
pekosz
yount
et
al
littl
influenc
vivo
viru
replic
mous
model
delet
orf
shown
minor
decreas
one
log
unit
viru
growth
yount
et
al
furthermor
delet
one
gene
delet
orf
show
log
reduct
vero
cell
littl
effect
growth
murin
model
day
postinfect
moreov
littl
differ
growth
pathogenesi
note
mice
model
wt
delet
mutant
lack
therefor
effect
sarscov
gene
delet
need
test
relev
anim
model
interestingli
simultan
delet
larger
combin
groupspecif
gene
lead
product
infecti
sarscov
deletionmut
propag
cell
cultur
titer
similar
parent
wild
type
viru
potenti
deletionmut
promis
vaccin
candid
studi
ml
dediego
l
enjuan
unpublish
result
recombin
sarscov
rsarscov
lack
e
gene
gener
bacteri
artifici
chromososm
bac
attenu
vitro
anim
model
dediego
et
al
e
gene
previous
shown
nonessenti
gene
group
mhv
coronaviru
kuo
master
although
elimin
gene
mhv
genom
reduc
viru
growth
cell
cultur
one
thousandfold
contrast
group
tgev
coronaviru
express
e
gene
product
essenti
viru
releas
spread
propag
e
gene
delet
tgev
tgeve
restor
provid
e
protein
tran
curti
et
al
ortego
et
al
role
e
protein
sarscov
propag
studi
construct
sarscov
delet
e
gene
dediego
et
al
interestingli
viabl
virus
recov
vero
cell
rel
high
titer
around
pfuml
also
cell
reduc
titer
fig
indic
sarscov
e
protein
essenti
viru
replic
cell
cultur
electron
microscopi
observ
vero
cell
infect
sarscov
wt
e
delet
mutant
show
much
higher
assembl
effici
wt
viru
fig
respect
sarscov
behav
mhv
group
coronaviru
studi
although
sarscov
grow
consider
higher
titer
differenti
behavior
e
mutant
virus
differ
coronaviru
group
may
indic
basic
differ
virion
assembl
life
cycl
among
differ
group
hamster
model
use
studi
sarscov
viru
pathogen
demonstr
element
present
human
case
sarscov
infect
includ
interstiti
pneumon
consolid
dediego
et
al
ideal
anim
model
complet
reproduc
human
clinic
diseas
patholog
find
identifi
nevertheless
hamster
model
reproduc
support
sarscov
replic
respiratori
tract
higher
titer
longer
durat
mice
nonhuman
primat
viru
replic
model
accompani
histolog
evid
pneumon
anim
develop
viremia
extrapulmonari
spread
viru
robert
et
al
although
overt
clinic
diseas
absent
hamster
model
use
model
evalu
sarscov
infect
titer
recombin
sarscov
rsarscov
achiev
respiratori
tract
hamster
fig
similar
previous
report
robert
et
al
higher
titer
rsarscov
viru
suggest
mutant
viru
attenu
histopatholog
examin
lung
infect
hamster
perform
two
five
day
postinfect
shown
pulmonari
diseas
notabl
time
point
detect
viral
antigen
reduc
lung
rsarscov
infect
hamster
pulmonari
inflamm
less
promin
anim
fig
growth
rsarscov
respiratori
tract
hamster
hamster
inocul
tcid
rsarscov
rsarscov
anim
sacrifi
tissu
harvest
differ
time
postinfect
viral
titer
lung
nasal
turbin
b
determin
vero
cell
monolay
nonparametr
mannwhitney
ustatist
method
use
ascertain
signific
observ
differ
statist
signific
indic
pvalu
dot
line
indic
lower
limit
detect
rsarscovinfect
anim
indic
rsarscov
attenu
vivo
dediego
et
al
fact
reduct
sarscov
titer
patient
associ
consider
reduct
pathogen
surviv
rate
hung
et
al
contrast
challeng
hamster
recombin
virus
lack
singl
group
specif
result
signific
reduct
viru
titier
patholog
baric
et
al
unpublish
therefor
sarscov
attenu
viru
promis
vaccin
candid
evalu
differ
anim
model
mice
ferret
macaqu
live
attenu
viru
vaccin
face
seri
potenti
concern
includ
revers
wt
recombin
repair
circul
heterogen
human
coronavirus
zoonot
sar
strain
consequ
live
viru
vaccin
formul
includ
ration
approach
minim
potenti
revers
wt
phenotyp
simultan
resist
recombin
repair
clear
modif
sarscov
genom
could
lead
virus
attenu
phenotyp
could
consid
safe
effect
vaccin
candid
replicas
target
attenu
coronavirus
undiscov
territori
like
ripe
allel
might
influenc
replic
effici
virul
sarscov
replicas
repres
major
target
futur
research
endeavor
coronavirus
characterist
strictli
conserv
genom
organ
structur
gene
occur
order
polymeras
pol
mhv
viru
mutant
gene
encod
structur
protein
locat
differ
order
construct
de
haan
et
al
recombin
virus
test
abil
replic
natur
host
mous
result
indic
canon
coronaviru
genom
organ
essenti
vivo
replic
mutant
show
attenu
phenotyp
similarli
observ
vsv
ball
et
al
therefor
deliber
rearrang
viral
gene
may
use
gener
attenu
coronavirus
due
reduc
risk
gener
viabl
virus
recombin
circul
field
virus
would
make
safer
vaccin
vaccin
base
modif
replicas
gene
could
principl
gener
mutagenesi
modif
introduc
mhv
region
identifi
residu
import
protein
process
viral
rna
replic
may
affect
viru
virul
could
introduc
vaccin
candid
sar
block
host
macromolecular
synthesi
abrog
ifn
signal
kamitani
et
al
provid
evid
code
region
repres
potenti
virul
determin
altern
substitut
open
read
frame
orf
demonstr
attenu
mhv
replic
mice
sperri
et
al
similarli
delet
gene
mhv
sarscov
shown
yield
viabl
attenu
mutant
virus
replic
one
log
less
effici
wt
viru
cell
cultur
anim
may
also
provid
foundat
design
live
vaccin
tyr
residu
nsp
complet
conserv
may
possibl
engin
common
coronavirida
attenu
allel
via
recombin
dna
techniqu
altern
chang
gene
order
within
replicas
even
reloc
end
genom
toler
may
led
attenu
viru
phenotyp
option
includ
safeguard
genet
engin
vaccin
particularli
prevent
recoveri
origin
virul
phenotyp
recombin
vaccin
strain
virus
circul
field
develop
one
construct
replicationcompet
propagationdefect
virus
pseudovirion
defect
one
gene
confer
attenu
phenotyp
even
abil
viru
propag
virus
could
grown
packag
cell
line
provid
tran
miss
protein
case
sarscov
vaccin
candid
without
e
gene
construct
order
prevent
rescu
virul
phenotyp
recombin
circul
human
coronaviru
delet
essenti
gene
locat
posit
distant
gene
e
reloc
delet
gene
posit
previous
occupi
gene
e
propos
potenti
recombin
lead
rescu
gene
e
would
lead
loss
essenti
gene
altern
approach
develop
safer
recombin
resist
live
coronaviru
vaccin
develop
modifi
transcript
regulatori
sequenc
tr
vaccin
strain
sequenc
incompat
tr
known
circul
coronaviru
idea
recombin
event
wt
coronavirus
tr
remodel
sarscov
would
result
genom
contain
lethal
mix
regulatori
sequenc
block
express
subgenom
mrna
fig
tr
sequenc
among
coronavirus
highli
conserv
direct
express
fig
genom
organ
sarscov
recombin
virus
gener
safe
attenu
virus
wildtyp
sarscov
tr
acgaac
blue
circl
chang
ccggat
red
circl
sinc
wildtyp
mutant
tr
signal
compat
regul
subgenom
transcript
recombin
event
result
viral
genom
mix
tr
signal
viabl
b
icsarscov
tr
sequenc
uniqu
describ
coronavirus
tr
sequenc
select
group
coronavirus
summar
tr
select
remodel
viru
shown
bottom
subgenom
mrna
use
molecular
clone
sarscov
tr
network
remodel
acgaac
ccggat
fig
rewir
genom
transcript
network
allow
effici
replic
mutant
viru
icsarscrg
icsarscrg
recombin
viru
replic
titer
equival
wt
viru
express
typic
ratio
subgenom
mrna
protein
interestingli
new
transcript
note
initi
replicas
gene
could
encod
ntermin
truncat
polyprotein
clear
novel
transcript
might
influenc
pathogen
outcom
although
instanc
truncat
potenti
allow
establish
domin
neg
phenotyp
replic
cell
cultur
anim
attract
sarscov
vaccin
could
modifi
build
attenu
mutat
genet
templat
recombinationresist
tr
rewir
viru
either
use
safe
high
titer
seed
stock
make
kill
vaccin
live
viru
vaccin
one
interest
refin
approach
would
includ
secondari
trap
activ
recombin
genom
instanc
wt
tr
sequenc
design
intragen
site
essenti
orf
like
glycoprotein
gene
recombin
virus
encod
wt
leader
tr
sequenc
subgenom
transcript
might
initi
within
essenti
structur
gene
result
ntermin
delet
would
like
lethal
sever
attenu
humor
tcellmedi
respons
anim
coronavirus
may
exacerb
diseas
caus
new
health
problem
tcell
respons
implic
demyelin
brain
spinal
cord
follow
infect
neurotrop
mhv
castro
perlman
wu
et
al
group
coronaviru
like
sarscov
advers
humor
respons
anoth
group
coronaviru
bovin
coronaviru
bcov
also
link
develop
ship
fever
cattl
oconnor
et
al
moreov
previou
exposur
fipv
passiv
activ
immun
viru
group
coronaviru
found
caus
earli
death
syndrom
instead
provid
immun
protect
pedersen
et
al
weiss
et
al
diseas
exacerb
due
virusspecif
antibodi
facilit
enhanc
uptak
spread
viru
caus
ade
infect
porterfield
vennema
et
al
weiss
scott
caus
spike
protein
specif
antibodi
corapi
et
al
corapi
et
al
olsen
et
al
olsen
et
al
scenario
side
effect
caus
coronaviru
vaccin
safeti
concern
sarscov
could
induc
similar
antibodyor
cellmedi
immun
patholog
concern
increas
mainli
three
report
one
studi
util
lentiviru
pseudotyp
variou
sarscov
protein
indic
within
protein
major
target
vaccin
immunotherapi
minor
differ
among
eight
strain
transmit
human
outbreak
earli
wherea
substanti
function
chang
detect
deriv
case
late
guandong
provinc
isol
two
palm
civet
spike
pseudotyp
viru
markedli
resist
antibodi
neutral
altern
antibodi
neutral
human
glycoprotein
enhanc
viru
entri
mediat
two
civet
cat
viru
glycoprotein
relat
isol
anoth
report
shown
administr
ferret
mvabas
sarscov
vaccin
mva
alon
follow
live
sarscov
challeng
result
enhanc
hepat
side
effect
report
studi
sarscov
ferret
shown
ferret
use
model
sarscov
martina
et
al
similarli
data
reproduc
group
et
al
furthermor
ade
diseas
observ
human
sarscov
strain
therefor
import
assess
vaccin
relev
anim
model
becom
avail
antibodi
direct
sarscov
found
protect
enhanc
viral
infect
mous
hamster
model
bisht
et
al
robert
et
al
yang
et
al
use
inactiv
sarscov
immun
recombin
adenoviru
vector
express
n
protein
sarscov
see
et
al
although
effect
human
remain
unknown
side
effect
observ
anim
model
african
green
monkey
month
administr
sarscov
respiratori
tract
challeng
sarscov
evid
enhanc
diseas
upon
rechalleng
shown
consist
result
cynomolgu
macaqu
immun
differ
amount
purifi
viru
absenc
presenc
adjuv
challeng
nasal
rout
day
postimmun
show
side
effect
even
presenc
low
titer
neutral
antibodi
temperatur
breath
appetit
mental
state
biochem
index
normal
immun
monkey
abnorm
observ
major
organ
lung
liver
kidney
etc
control
nonvaccin
anim
show
interstiti
pneumonia
result
indic
purifi
sarscov
vaccin
safe
monkey
qin
et
al
summari
immun
mice
use
either
protein
whole
inactiv
viru
spruth
et
al
monkey
whole
inactiv
sarscov
qin
et
al
zhou
et
al
frequent
result
absenc
side
effect
provid
differ
type
sarscov
vaccin
contrast
vee
viru
express
n
protein
fail
induc
protect
either
young
senesc
anim
result
enhanc
immunopatholog
follow
viral
challeng
day
postinfect
therefor
caution
taken
includ
n
vaccin
formul
express
n
protein
use
dna
immun
vee
vector
protect
elicit
mice
homolog
challeng
benefit
vaccin
cocktail
n
protein
observ
rather
coexpress
n
protein
vaccin
regimen
fail
simultan
induc
strong
neutral
anti
antibodi
respons
led
increas
number
lymphocyt
eosinophil
inflammatori
infiltr
also
characterist
immun
patholog
observ
respiratori
syncyti
viru
rsv
infect
follow
vaccin
formalin
inactiv
rsv
de
swart
et
al
hancock
et
al
therefor
concern
rais
express
n
protein
may
result
vaccineenhanc
pulmonari
diseas
previous
describ
virus
like
rsv
kim
et
al
data
suggest
presenc
n
protein
vaccin
evalu
vaccin
formul
although
thu
far
human
sarscov
vaccin
shown
involv
ade
diseas
possibl
immunopatholog
complic
sar
vaccin
candid
requir
rigor
clinic
immunolog
evalu
wherea
product
effect
safe
vaccin
anim
coronaviru
previous
report
satisfactori
cavanagh
enjuan
et
al
saif
product
inactiv
subunit
vaccin
base
dna
recombin
vector
revers
genet
use
sarscov
genom
seem
promis
optimum
anim
model
sarscov
vaccin
evalu
still
requir
preclin
trial
anim
model
efficaci
safeti
evalu
promis
vaccin
candid
describ
perform
human
